Ependymoma is a primary central nervous system (CNS) tumor that arises from ependymal cells lining the ventricular system of the brain and the central canal of the spinal cord. These tumors affect individuals of any age, presenting distinct characteristics and behaviors based on their location and histological grade.
Ependymoma is a type of primary central nervous system (CNS) tumor that arises from ependymal cells, which line the ventricular system of the brain and the central canal of the spinal cord. These tumors can occur at any age, but they are most frequently diagnosed in children, particularly in the posterior fossa of the brain. In adults, spinal cord involvement is more common. The behavior and progression of ependymomas vary depending on their histological subtype and anatomical location. This includes cases of brain ependymoma, where the tumor develops in intracranial locations and impacts CSF dynamics.
What Causes Ependymoma?
Ependymomas originate from glial-derived ependymal cells responsible for producing and circulating cerebrospinal fluid (CSF). While the exact cause remains unclear, genetic mutations and chromosomal abnormalities, such as chromosome 22q deletions, are believed to contribute to tumor formation, particularly in pediatric cases. Intracranial forms such as ependymoma of brain often show distinct molecular alterations.
WHO Classification of Ependymoma
The World Health Organization (WHO) classifies ependymomas into three major categories based on histopathological and molecular features:
Grade 1: Subependymoma, Myxopapillary Ependymoma
These are slow-growing, typically non-invasive, and often discovered incidentally.
Grade 2: Classic Ependymoma
Exhibit moderate proliferative activity, with potential for local recurrence.
Grade 3: Anaplastic Ependymoma
These are high-grade, malignant tumors that grow more rapidly and have a higher likelihood of recurrence and poor prognosis. The anaplastic ependymoma subtype demands aggressive multimodal management strategies.
Recent WHO classifications also emphasize molecular subtypes such as posterior fossa group A (PFA) and group B (PFB), which have different outcomes and treatment implications.
Common Symptoms of Ependymoma
Symptoms depend on tumor size, growth rate, and most importantly, location within the brain or spinal cord. Tumors obstructing CSF flow may lead to elevated intracranial pressure and hydrocephalus. In cases involving the brain, especially ependymoma brain tumors, early signs may mimic other intracranial mass lesions. Frequently observed symptoms include:
- Persistent Headaches and Nausea: Resulting from increased intracranial pressure due to CSF obstruction.
- Hydrocephalus: Enlargement of cerebral ventricles, especially in infratentorial tumors, leading to symptoms like vomiting, lethargy, or visual changes.
- Visual Disturbances: Such as double vision, blurry vision, or visual field deficits.
- Gait Instability and Muscle Weakness: Resulting from compression of motor tracts or spinal cord involvement.
- Seizures: More likely when the tumor is located in the supratentorial region.
How Is Ependymoma Diagnosed?
A combination of neurological evaluation, neuroimaging, and histopathological confirmation is essential for diagnosis. Diagnostic steps:
- Neurological Examination: Evaluates reflexes, muscle strength, balance, and sensory deficits.
- Magnetic Resonance Imaging (MRI): The imaging modality of choice. Ependymoma radiology findings on MRI: Tumors appear as well-demarcated lesions, often showing contrast enhancement. In spinal cord cases, they may extend across several vertebral levels.
Treatment Options for Ependymoma
Optimal management of ependymoma relies on a multidisciplinary strategy involving neurosurgeons, neuro-oncologists and radiation oncologists. The treatment plan varies according to the tumor's location, grade, and patient’s overall health status.
1. Microsurgical Resection
The first-line treatment is maximal safe microsurgical removal of the tumor. Total resection improves survival and reduces the likelihood of recurrence. In certain cases—especially in eloquent brain regions—intraoperative neuromonitoring and navigation systems are utilized to minimize neurological damage.
Surgery is not only performed to control symptoms like hydrocephalus or mass effect but also to enable histopathological diagnosis and guide further therapy.
2. Radiation Therapy
Postoperative radiotherapy is standard for incompletely resected or high-grade tumors.
Proton beam therapy is increasingly used, especially in pediatric patients, to reduce radiation exposure to surrounding healthy brain tissues.
Craniospinal irradiation may be considered in cases with CSF dissemination.
3. Chemotherapy
The role of chemotherapy remains limited but may be employed in ependymoma anaplastic, recurrent disease, or infants where radiotherapy is deferred.
Protocols often include platinum-based agents or etoposide in clinical trial settings.
Prognosis and Follow-up
The prognosis of ependymoma is highly variable and depends on several factors:
- Tumor Grade and Subtype: Low-grade tumors have favorable outcomes with gross total resection, while anaplastic forms carry a worse prognosis.
- Extent of Surgical Resection: Complete removal is the strongest predictor of long-term survival.
- Age at Diagnosis and Tumor Location: Younger age and infratentorial location often require closer monitoring.
Long-term MRI surveillance is essential, particularly for high-grade or incompletely resected tumors. Survivorship care also includes neurocognitive assessments, endocrinological evaluations, and psychosocial support.
Conclusion
Ependymomas are complex CNS tumors with diverse presentations depending on their grade, anatomical site, and molecular profile. While surgical resection remains the mainstay of treatment, radiotherapy and chemotherapy may also play important roles in selected cases. Early diagnosis, individualized treatment planning, and a collaborative, multidisciplinary approach are key to improving survival rates and quality of life in both pediatric and adult patients.
Frequently Asked Questions
What is an ependymoma?
Ependymoma is a type of primary central nervous system (CNS) tumor that arises from ependymal cells, which line the ventricular system of the brain and the central canal of the spinal cord. These tumors can occur at any age, but are most frequently diagnosed in children in the posterior fossa of the brain, whereas spinal cord involvement is more common in adults.
What are the WHO grades of ependymoma?
The World Health Organization (WHO) classifies ependymomas into Grade 1 (Subependymoma, Myxopapillary Ependymoma), Grade 2 (Classic Ependymoma), and Grade 3 (Anaplastic Ependymoma). Grade 1 tumors are slow-growing and non-invasive, Grade 2 show moderate proliferative activity, and Grade 3 are high-grade malignant tumors that grow rapidly.
What are the most common symptoms of brain ependymoma?
Common symptoms include persistent headaches and nausea, hydrocephalus (enlargement of cerebral ventricles), visual disturbances such as double or blurry vision, gait instability, muscle weakness, and seizures, depending on the tumor's size and location.
How is ependymoma diagnosed?
Diagnosis requires a combination of neurological evaluation, neuroimaging, and histopathological confirmation. Magnetic Resonance Imaging (MRI) is the primary imaging modality of choice to visualize well-demarcated lesions and evaluate tumor extension.
What is the primary treatment for ependymoma?
The first-line treatment is maximal safe microsurgical removal of the tumor. Postoperative radiation therapy or chemotherapy may be used depending on tumor grade, surgical completeness, and patient age.
What factors affect the prognosis of ependymoma?
Prognosis depends on the tumor grade and subtype, the extent of surgical resection, age at diagnosis, and tumor location. Complete surgical removal is the strongest predictor of long-term survival.